Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Liabilities and Shareholders Equity (2020 - 2025)

Ovid Therapeutics' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $150.9 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 63.76% year-over-year to $150.9 million; the TTM value through Dec 2025 reached $373.9 million, down 15.9%, while the annual FY2025 figure was $150.9 million, 63.76% up from the prior year.
  • Liabilities and Shareholders Equity reached $150.9 million in Q4 2025 per OVID's latest filing, up from $63.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $237.5 million in Q1 2021 to a low of $63.8 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $145.6 million, with a median of $143.7 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 380.65% in 2021, then crashed 37.96% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $194.5 million in 2021, then fell by 20.19% to $155.3 million in 2022, then dropped by 7.24% to $144.0 million in 2023, then plummeted by 36.01% to $92.2 million in 2024, then soared by 63.76% to $150.9 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Liabilities and Shareholders Equity are $150.9 million (Q4 2025), $63.8 million (Q3 2025), and $77.4 million (Q2 2025).